Thrombosis Medicine Center, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, 100037.
Curr Hypertens Rep. 2013 Dec;15(6):638-49. doi: 10.1007/s11906-013-0397-5.
The epidemiology of pulmonary arterial hypertension (PAH) has changed over the last decade. Remarkable advances in understanding the pathobiology and clinical care required in PAH have resulted in improved quality of life and survival. Despite such important progress, the long-term rate of survival is still unacceptable. The epidemiology of PAH could not be easily generalized globally, due to the fact that nearly all of the present data has been gathered from Western, multicenter, prospective registries. There are potentially marked differences in PAH patients from Western and Eastern populations, and from developed and developing countries. Therefore, it is clear that more registry data will be needed to address novel questions emerging with improved knowledge of PAH.
肺动脉高压(PAH)的流行病学在过去十年中发生了变化。对 PAH 的病理生物学和临床治疗的理解取得了显著进展,从而提高了生活质量和生存率。尽管取得了如此重要的进展,但长期生存率仍然不能令人接受。由于目前几乎所有的资料都是来自西方多中心前瞻性登记处,因此 PAH 的流行病学不能轻易地在全球范围内推广。来自西方和东方人群、发达国家和发展中国家的 PAH 患者之间可能存在明显差异。因此,显然需要更多的登记数据来解决随着对 PAH 认识的提高而出现的新问题。